PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Bioaraba Health Research Institute, Epidemiology and Public Health Research Group, Vitoria-Gasteiz, Spain. Electronic address: RAQUEL.COBOSCAMPOS@osakidetza.eus.\', \'Bioaraba Health Research Institute, Epidemiology and Public Health Research Group, Vitoria-Gasteiz, Spain; Osakidetza Basque Health Service, Aranbizkarra I Health Centre, Vitoria-Gasteiz, Spain; Department of Preventive Medicine and Public Health, EHU/UPV, Vitoria-Gasteiz, Spain. Electronic address: ANTXON.APINANIZFERNANDEZ@osakidetza.eus.\', \'Bioaraba Health Research Institute, Epidemiology and Public Health Research Group, Vitoria-Gasteiz, Spain. Electronic address: NAIARA.PARRAZADIEZ@osakidetza.eus.\', \'Bioaraba Health Research Institute, Epidemiology and Public Health Research Group, Vitoria-Gasteiz, Spain. Electronic address: JOSEAURELIO.CORDEROGUEVARA@osakidetza.eus.\', \'Bioaraba Health Research Institute, Epidemiology and Public Health Research Group, Vitoria-Gasteiz, Spain. Electronic address: SAINZA.GARCIAFERNANDEZ@osakidetza.eus.\', \'Bioaraba Health Research Institute, Epidemiology and Public Health Research Group, Vitoria-Gasteiz, Spain. Electronic address: ESTIBALITZ.ORRUNOAGUADO@osakidetza.eus.\']
?:citedBy
  • -1
?:creator
?:doi
  • S2452-3186(21)00035-010.1016/j.retram.2021.103309
?:doi
?:hasPublicationType
?:journal
  • Current research in translational medicine
is ?:pmid of
?:pmid
?:pmid
  • 34418758
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.69
?:rankingScore_hIndex
  • 51
is ?:relation_isRelatedTo_publication of
?:title
  • Potential use of ivermectin for the treatment and prophylaxis of SARS-CoV-2 infection.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all